Cargando…
The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1)
The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-relate...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169230/ https://www.ncbi.nlm.nih.gov/pubmed/35405261 http://dx.doi.org/10.1016/j.nbd.2022.105722 |
_version_ | 1784721164375949312 |
---|---|
author | Johnson, Michelle A. Klickstein, Jacob A. Khanna, Richa Gou, Yunzi Raman, Malavika |
author_facet | Johnson, Michelle A. Klickstein, Jacob A. Khanna, Richa Gou, Yunzi Raman, Malavika |
author_sort | Johnson, Michelle A. |
collection | PubMed |
description | The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts. |
format | Online Article Text |
id | pubmed-9169230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-91692302022-07-01 The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) Johnson, Michelle A. Klickstein, Jacob A. Khanna, Richa Gou, Yunzi Raman, Malavika Neurobiol Dis Article The 2021 VCP Scientific Conference took place virtually from September 9–10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts. 2022-07 2022-04-08 /pmc/articles/PMC9169230/ /pubmed/35405261 http://dx.doi.org/10.1016/j.nbd.2022.105722 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Johnson, Michelle A. Klickstein, Jacob A. Khanna, Richa Gou, Yunzi Raman, Malavika The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title | The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title_full | The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title_fullStr | The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title_full_unstemmed | The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title_short | The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) |
title_sort | cure vcp scientific conference 2021: molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (msp-1) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169230/ https://www.ncbi.nlm.nih.gov/pubmed/35405261 http://dx.doi.org/10.1016/j.nbd.2022.105722 |
work_keys_str_mv | AT johnsonmichellea thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT klicksteinjacoba thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT khannaricha thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT gouyunzi thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT ramanmalavika thecurevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT johnsonmichellea curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT klicksteinjacoba curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT khannaricha curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT gouyunzi curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 AT ramanmalavika curevcpscientificconference2021molecularandclinicalinsightsintoneurodegenerationandmyopathylinkedtomultisystemproteinopathy1msp1 |